ENZ
ENZ Real Time Price USDRecent trades of ENZ by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ENZ holdings by institutional investors
Quarterly net insider trading by ENZ's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
ENZ Estimated quarterly lobbying spending
ENZ Revenue by Segment or Geography
New ENZ patent grants
-
Patent Title: Dna labeling compositions and methods for comparative genomic hybridization Oct. 14, 2025
-
Patent Title: Fluorescence quencher polymer conjugates and uses thereof Oct. 22, 2024
-
Patent Title: Diagnosis and treatment of viral diseases Aug. 13, 2024
-
Patent Title: Pharmaceutical compositions and methods targeting wnt pathway proteins Mar. 26, 2024
-
Patent Title: Sphingosine pathway modulating compounds for the treatment of coronavirus infection Mar. 19, 2024
-
Patent Title: Sphingosine pathway modulating compounds for the treatment of cancers Jan. 09, 2024
-
Patent Title: Sphingosine pathway modulating compounds for the treatment of coronavirus infection Aug. 15, 2023
-
Patent Title: Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor Jun. 06, 2023
-
Patent Title: Antibodies specific for sulfation sites of wnt pathway proteins May. 02, 2023
-
Patent Title: Sphingosine pathway modulating compounds for the treatment of coronavirus infection Jan. 17, 2023
-
Patent Title: Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta Nov. 16, 2021
-
Patent Title: Methods for treating bone loss using sclerostin peptides Nov. 09, 2021
-
Patent Title: Affinity tag nucleic acid and protein compositions, and processes for using same Jul. 20, 2021
-
Patent Title: Antibodies specific for sulfation sites of sclerostin Jan. 26, 2021
-
Patent Title: Sphingosine pathway modulating compounds for the treatment of cancers Jan. 05, 2021
-
Patent Title: Monoazo dyes with cyclic amine as fluorescence quenchers Dec. 15, 2020
-
Patent Title: Immunomodulatory pharmaceutical compositions Jul. 14, 2020
-
Patent Title: Methods and intermediates for synthesizing sk1-i Jun. 16, 2020
-
Patent Title: Sphingosine pathway modulating compounds for the treatment of cancers May. 26, 2020
-
Patent Title: Sphingosine pathway modulating compounds for the treatment of cancers May. 12, 2020
-
Patent Title: Diagnosis and treatment of viral diseases Dec. 03, 2019
-
Patent Title: Methods and intermediates for synthesizing sk1-i Jul. 30, 2019
-
Patent Title: Monoazo dyes with cyclic amine as fluorescence quenchers May. 01, 2018
-
Patent Title: Monoazo dyes with cyclic amine as fluorescence quenchers Apr. 24, 2018
-
Patent Title: Diagnosis and treatment of viral diseases Apr. 03, 2018
-
Patent Title: Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications Apr. 03, 2018
-
Patent Title: Compositions and processes for analyte detection, quantification and amplification Jan. 23, 2018
-
Patent Title: Process for detecting or quantifying nucleic acids in a library Oct. 03, 2017
-
Patent Title: Process for detecting or quantifying nucleic acids in a library Sep. 19, 2017
-
Patent Title: Process for detecting or quantifying nucleic acids in a library Aug. 29, 2017
-
Patent Title: Processes for detecting or quantifying nucleic acids using an array of fixed or immobilized nucleic acids May. 16, 2017
-
Patent Title: Processes for detecting or quantifying nucleic acids using an array of fixed or immobilized nucleic acids May. 02, 2017
-
Patent Title: Diagnosis and treatment of viral diseases Apr. 11, 2017
-
Patent Title: Processes for detecting or quantifying nucleic acids using an array of fixed or immobilized nucleic acids Apr. 11, 2017
-
Patent Title: Method for treating crohn's disease or ulcerative colitis by administering a compound which binds ldl-receptor-related protein (lrp) ligand binding domain Nov. 15, 2016
-
Patent Title: Autophagy and phospholipidosis pathway assays Feb. 02, 2016
-
Patent Title: Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications Sep. 15, 2015
-
Patent Title: Compounds and assays for controlling wnt activity Jun. 09, 2015
-
Patent Title: Method for treating inflammation by administering a compound which binds ldl-receptor-related protein (lrp) ligand binding domain Jun. 02, 2015
-
Patent Title: Compositions and methods for bone formation and modeling Mar. 03, 2015
-
Patent Title: Non-ionically bound constructs, and compositions and kits comprising domains Sep. 30, 2014
-
Patent Title: Transmucosal administration of aggregated antigens Jun. 24, 2014
-
Patent Title: Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses Jun. 03, 2014
-
Patent Title: Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses May. 27, 2014
-
Patent Title: Compositions and methods for bone formation and remodeling Jan. 28, 2014
-
Patent Title: Fluorescent dyes and compounds, methods and kits useful for identifying specific organelles and regions in cells of interest Jan. 29, 2013
-
Patent Title: Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells Jan. 01, 2013
-
Patent Title: Polynucleotides comprising intercalating entities Dec. 18, 2012
-
Patent Title: Selective detection of oncogenic hpv Feb. 28, 2012
-
Patent Title: Nucleic acid sequencing processes using non-radioactive detectable modified or labeled nucleotides or nucleotide analogs, and other processes for nucleic acid detection and chromosomal characterization using such non-radioactive detectable modified or labeled nucleotides or nucleotide analogs Jan. 17, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ENZ from public contracts
Recent insights relating to ENZ
Recent picks made for ENZ stock on CNBC
ETFs with the largest estimated holdings in ENZ
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ENZ stock a Buy, Sell, or Hold?
- What is the price target for $ENZ stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ENZ stock?
- Who owns the most shares of $ENZ stock?
- What funds own $ENZ stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ENZ Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
No description available